Table 1.

Characteristics of Study Participants (Total Vaccinated Cohort)

CharacteristicTotal
(N = 430)
HZ-NonVac
(n = 215)
HZ-PreVac
(n = 215)
Age, mean (SD)70.9 (4.6)70.8 (4.6)71.1 (4.5)
Sex, No (%)
Female220 (51.2)111 (51.6)109 (50.7)
Male210 (48.8)104 (48.4)106 (49.3)
White/European ancestry, No. (%)430 (100)215 (100)215 (100)
CharacteristicTotal
(N = 430)
HZ-NonVac
(n = 215)
HZ-PreVac
(n = 215)
Age, mean (SD)70.9 (4.6)70.8 (4.6)71.1 (4.5)
Sex, No (%)
Female220 (51.2)111 (51.6)109 (50.7)
Male210 (48.8)104 (48.4)106 (49.3)
White/European ancestry, No. (%)430 (100)215 (100)215 (100)

Abbreviations: HZ-NonVac, participants who never received the live attenuated zoster vaccine; HZ-PreVac, participants who received the live attenuated zoster vaccine ≥5 years prior to study start; N/n, number of participants; SD, standard deviation.

Table 1.

Characteristics of Study Participants (Total Vaccinated Cohort)

CharacteristicTotal
(N = 430)
HZ-NonVac
(n = 215)
HZ-PreVac
(n = 215)
Age, mean (SD)70.9 (4.6)70.8 (4.6)71.1 (4.5)
Sex, No (%)
Female220 (51.2)111 (51.6)109 (50.7)
Male210 (48.8)104 (48.4)106 (49.3)
White/European ancestry, No. (%)430 (100)215 (100)215 (100)
CharacteristicTotal
(N = 430)
HZ-NonVac
(n = 215)
HZ-PreVac
(n = 215)
Age, mean (SD)70.9 (4.6)70.8 (4.6)71.1 (4.5)
Sex, No (%)
Female220 (51.2)111 (51.6)109 (50.7)
Male210 (48.8)104 (48.4)106 (49.3)
White/European ancestry, No. (%)430 (100)215 (100)215 (100)

Abbreviations: HZ-NonVac, participants who never received the live attenuated zoster vaccine; HZ-PreVac, participants who received the live attenuated zoster vaccine ≥5 years prior to study start; N/n, number of participants; SD, standard deviation.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close